Celon Pharma SA (CLN) — Net Asset Quality Index
Celon Pharma SA (CLN) has a Net Asset Quality Index of 79.4% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of zł457.46 Million minus total liabilities of zł94.21 Million yields net assets of zł363.25 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check CLN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Celon Pharma SA Net Asset Quality Index Over Time (2012–2025)
This chart shows how Celon Pharma SA's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the index stands at 79.4%, representing net assets of zł363.25 Million against total assets of zł457.46 Million PLN. See Celon Pharma SA short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Celon Pharma SA (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Celon Pharma SA from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of Celon Pharma SA.
| Year | Quality Index | Net Assets (PLN) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 79.4% | zł363.25 Million | zł457.46 Million | zł94.21 Million | ▼ -2.5 pp |
| 2024 | 81.9% | zł445.21 Million | zł543.79 Million | zł98.59 Million | ▲ +3.6 pp |
| 2023 | 78.3% | zł445.56 Million | zł569.31 Million | zł123.75 Million | ▼ -0.5 pp |
| 2022 | 78.8% | zł479.65 Million | zł608.93 Million | zł129.29 Million | ▲ +0.4 pp |
| 2021 | 78.3% | zł554.00 Million | zł707.14 Million | zł153.14 Million | ▲ +16.6 pp |
| 2020 | 61.8% | zł434.67 Million | zł703.64 Million | zł268.97 Million | ▼ -13.5 pp |
| 2019 | 75.3% | zł445.04 Million | zł591.35 Million | zł146.31 Million | ▼ -4.3 pp |
| 2018 | 79.6% | zł448.73 Million | zł563.67 Million | zł114.94 Million | ▼ -4.2 pp |
| 2017 | 83.8% | zł439.85 Million | zł525.05 Million | zł85.20 Million | ▼ -2.9 pp |
| 2016 | 86.7% | zł402.50 Million | zł464.32 Million | zł61.82 Million | ▲ +26.8 pp |
| 2015 | 59.9% | zł100.82 Million | zł168.29 Million | zł67.47 Million | ▼ -6.1 pp |
| 2014 | 66.0% | zł69.62 Million | zł105.44 Million | zł35.82 Million | ▲ +2.8 pp |
| 2013 | 63.2% | zł52.20 Million | zł82.59 Million | zł30.39 Million | ▼ -16.4 pp |
| 2012 | 79.6% | zł55.57 Million | zł69.80 Million | zł14.22 Million | — |